Spero Therapeutics to Participate at the Berenberg Conference USA

Rhea-AI Summary

On May 13, 2021, Spero Therapeutics (Nasdaq: SPRO) announced that CEO Ankit Mahadevia will participate in a virtual fireside chat at the Berenberg Conference USA, scheduled for May 18, 2021, at 2:00 PM ET. The event will discuss Spero's focus on combating multi-drug resistant bacterial infections and rare diseases. Investors can access the chat through a provided webcast link. Spero's key product, tebipenem HBr, is being developed as the first oral carbapenem antibiotic for complicated urinary tract infections. More about Spero can be found on their website.

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the Berenberg Conference USA, taking place virtually from May 18 – 20, 2021. Details for the fireside chat are as follows:

Berenberg Conference USA

Fireside Chat Date & Time: Tuesday, May 18 at 2:00 PM ET

Webcast Link: Register Here

A webcast of the fireside chat may also be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Investors and Media” tab. A replay of the fireside chat will be archived on the website for 90 days following the conclusion of the event.

About Spero Therapeutics

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

Spero is also developing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.

Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Investor Relations Contact:

Ashley Robinson
LifeSci Advisors
arr@lifesciadvisors.com
617-430-7577

Media Contact:

media@sperotherapeutics.com

FAQ

What is Spero Therapeutics participating in on May 18, 2021?

Spero Therapeutics is participating in a fireside chat at the Berenberg Conference USA, taking place virtually.

What time is the Spero Therapeutics fireside chat scheduled for?

The fireside chat is scheduled for May 18, 2021, at 2:00 PM ET.

Where can I watch the Spero Therapeutics fireside chat?

The fireside chat can be watched through a webcast link provided in their press release or on Spero Therapeutics' website.

What is the focus of Spero Therapeutics?

Spero Therapeutics focuses on developing treatments for multi-drug resistant bacterial infections and rare diseases.

What is tebipenem HBr?

Tebipenem HBr is Spero's lead product candidate, being developed as the first oral carbapenem antibiotic for complicated urinary tract infections.